CLINUVEL PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.57 AUD | -2.80% |
|
+1.32% | -8.94% |
| Mar. 14 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
| Mar. 14 | Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16 | MT |
Presenter SpeechVerity Wai-Smith (Attendees)Good evening, everyone. I'm Verity from Monsoon Co...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Clinuvel Pharmaceuticals Limited is a global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. The Company is engaged in managing and expanding commercial distribution of its lead drug candidate, SCENESSE, in Europe, the United States, Israel, and Australia for the treatment of a rare, genetic metabolic disorder, erythropoietic protoporphyria (EPP). The Companyâs pipeline includes PRENUMBRA, NEURACTHEL, CUV9900, and Parvysmelanotide (VLRX001). PRENUMBRA is a liquid (non-solid) injectable formulation of afamelanotide designed to provide a flexible dose of afamelanotide, a synthetic analogue of natural a-melanocyte stimulating hormone. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH), for neurological, endocrinological and degenerative disorders.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
14.57
AUD
Average target price
25.6
AUD
Spread / Average Target
+75.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.94% | 476M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- CUV Stock
- News Clinuvel Pharmaceuticals Limited
- Transcript : Clinuvel Pharmaceuticals Limited, H1 2024 Earnings Call, Feb 22, 2024
